There’s a long-touted assertion that it takes approximately 17 years for evidence to transition to practice in healthcare. In many cases, it takes even longer than that, and it will continue to do so until we ensure that the research answers two definitive questions: So what will be the outcome(s) of the study when completed? So what difference will that study make in improving healthcare quality, costs, or patient outcomes?
Trying to make decisions about which healthcare technology to acquire, the appropriate timing of these acquisitions, and the utilization of these products can feel like an endless game show episode. The movement toward a value-based healthcare delivery system has left healthcare organizations scratching their heads to come up with the answers about how to make the most cost-efficient and clinically effective purchases and deployment decisions that will enhance patient outcomes without negatively affecting the bottom line. Both clinical leadership and supply chain coordinators want to know: can I phone a friend? Do I have a 50/50?
It seems only fitting that we held our inaugural Client Symposium by the historic Philadelphia waterfront. We’ve envisioned ourselves as a lighthouse, shining a light on the best available evidence and providing you with decision-making tools to establish best practices and deliver value-based medicine. Although today’s technology has made it possible for us to work with our partners remotely all over the world, we recognized the need and benefit of face-to-face interactions. After nearly thirty years in business, we called the ships to shore, allowing us all the opportunity to reunite, recognize, and reinvigorate our journey to improve the provision of evidence-based healthcare.
Population health management (PHM) requires collaboration between clinicians across the care continuum, much like a symphony requires coordination among multiple musicians. In the case of the orchestra, everyone has matching sheet music, ensuring consistency and harmony.
When managing your population’s health, the “sheet music” that guides a cohesive, orchestrated approach to patient care is evidence-based medicine (EBM). Traditionally, physicians making diagnoses or treatment decisions based solely upon their individual experience and education. EBM can augment the physician’s experiential background or to set standards for enterprise-wide best practices.
Topics: Hayes Blog
There are more than 65,000 genetic tests available on the market today and new genetic tests are added daily. According to the website GeneTests.org, there are currently more than 650 laboratories manufacturing tests for more than 4,500 disorders. The quick math? There are potentially thousands of different tests for a clinical indication. But how do payers and providers even begin to identify when genetic testing can be useful, let alone which test to use?
The Hayes Client Symposium is under two months away and our accredited sessions are taking shape for our clients who are attending. Few areas of healthcare are changing as rapidly as the field of genetics—from new tests coming to market weekly, to proposed changes in regulation. We’re pleased to be offering a session focused on this evolving topic.
The term “evidence-based” has been juggled around in healthcare for years. Many companies use the term, but few provide the necessary details to support the claim. In particular, use of the term “evidence-based” has exploded among companies providing IT-based solutions for payers and providers. In the health plan space, insurance companies are required to meet a burden of proof that evidence-based resources are being utilized in order to qualify for National Committee for Quality Assurance (NCQA) accreditation status. Similarly, in the health system space, evidence-based guidelines have become the standard as physicians strive to reduce clinical variation.
The Hayes Client Symposium is just about 3 months away and we’re busy preparing our accredited sessions for our health plan clients who will be in attendance. I’m personally excited to be part of the session focusing on the FDA approval process and the impact this has on coverage policy. This is always a hot topic for our health plan clients.
Some background about the FDA:
The Food and Drug Administration (FDA) can trace its origins as a federal consumer protection agency to the passage of the 1906 Pure Food and Drugs Act. The 1906 Act was passed in response to public outrage at the startlingly unsanitary conditions in the Chicago meatpacking industry described by Upton Sinclair in his landmark book, The Jungle.
Hospitals do not need to be reminded of technology acquisition mistakes they may have made in the past. They simply need to look in the operating room to see the pile of abandoned equipment.
Hospitals and healthcare systems can ill afford to make mistakes when evaluating and acquiring health technologies. However, technology by its nature is always changing. New products are constantly emerging but often there is limited evidence on safety, effectiveness, and cost.
Having the flu is a truly miserable experience—especially in the heat of summer. Symptoms include fever, chills, muscle aches, cough, congestion, runny nose, headaches and fatigue. Unfortunately, once flu germs have taken up residence in your body, there is little that can be done except to treat the symptoms and wait it out.